

IMMUNOMEDICS INC  
Form 8-K  
May 22, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 21, 2008

Immunomedics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	000-12104 (Commission File Number)	61-1009366 (IRS Employer Identification No.)
---------------------------------------------------------------	---------------------------------------	-------------------------------------------------

300 American Road, Morris Plains, New Jersey (Address of Principal Executive Offices)	07950 (Zip Code)
------------------------------------------------------------------------------------------	---------------------

(973) 605-8200  
(Registrant's telephone number,  
including area code)

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
- 

Item 8.01. Other Events.

On May 21, 2008, Immunomedics, Inc., a Delaware corporation (the "Company"), received \$6.0 million from the sale of two auction rate securities at par value plus accrued interest. The Company continues to hold six auction rate securities with par value of \$23 million in the aggregate. The Company does not intend to hold its remaining auction rate securities to maturity, and will continue to monitor transactions in the auction rate securities market for possible

liquidation on terms that are acceptable for the Company.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan

Name:Cynthia L. Sullivan

Title:President and Chief Executive Officer

Date: May 22, 2008